TY - JOUR
T1 - Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine
T2 - what is the opinion of Italian oncologists?
AU - Cazzaniga, Marina E.
AU - Munzone, Elisabetta
AU - Montagna, Emilia
AU - Pappagallo, Giovanni
PY - 2018/8/3
Y1 - 2018/8/3
N2 - Background: The aim of this study was to record the opinions of Italian oncologists about the use of oral vinorelbine administered metronomically in patients with advanced breast cancer. Methods: A series of meetings were held throughout Italy, and participants were asked how much they agreed with each of the several statements. Results: The majority of oncologists agreed that the concept of the minimum biologically effective dose should be used for drugs administered metronomically. Over 50% agreed that metronomic vinorelbine is an option in first-line chemotherapy for patients with advanced breast cancer, including those with a terminal illness and the elderly, as well as in young and fit patients. Just over one-third of experts agreed that a combination of two chemotherapy agents instead of one is not desirable in metastatic breast cancer because of increased toxicity. Most experts agreed that the main aim of a first-line therapy is to control the disease over time and to preserve quality of life. Conclusion: Metronomically administered oral vinorelbine, either as monotherapy or in combination with other drugs, is effective in the long-term treatment of patients with advanced breast cancer. The clinical profiles of patients should be carefully considered to determine the appropriate treatment strategy.
AB - Background: The aim of this study was to record the opinions of Italian oncologists about the use of oral vinorelbine administered metronomically in patients with advanced breast cancer. Methods: A series of meetings were held throughout Italy, and participants were asked how much they agreed with each of the several statements. Results: The majority of oncologists agreed that the concept of the minimum biologically effective dose should be used for drugs administered metronomically. Over 50% agreed that metronomic vinorelbine is an option in first-line chemotherapy for patients with advanced breast cancer, including those with a terminal illness and the elderly, as well as in young and fit patients. Just over one-third of experts agreed that a combination of two chemotherapy agents instead of one is not desirable in metastatic breast cancer because of increased toxicity. Most experts agreed that the main aim of a first-line therapy is to control the disease over time and to preserve quality of life. Conclusion: Metronomically administered oral vinorelbine, either as monotherapy or in combination with other drugs, is effective in the long-term treatment of patients with advanced breast cancer. The clinical profiles of patients should be carefully considered to determine the appropriate treatment strategy.
KW - Advanced breast cancer
KW - antiangiogenesis
KW - immunomodulation
KW - metronomic chemotherapy
KW - vinorelbine
UR - http://www.scopus.com/inward/record.url?scp=85049597328&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049597328&partnerID=8YFLogxK
U2 - 10.1080/14737140.2018.1489244
DO - 10.1080/14737140.2018.1489244
M3 - Article
C2 - 29902087
AN - SCOPUS:85049597328
VL - 18
SP - 805
EP - 814
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
SN - 1473-7140
IS - 8
ER -